JP6881984B2 - Binge eating inhibitor - Google Patents

Description

The present invention relates to a binge eating inhibitor.

Obesity is a state of being fat, and the Japan Society for the Study of Obesity defines a BMI (Body Mass Index) of 25 or higher as obesity. Obesity that occurs because the energy ingested in the diet exceeds the energy consumed is called simple obesity (primary obesity), and 95% of all obesity is said to be this simple obesity. It is said that Japanese people are more likely to have impaired glucose tolerance, dyslipidemia, hypertension and other health disorders from around BMI 25, and preventing and improving obesity is to prevent the onset and progression of arteriosclerosis and diabetes. Is also important for.
The principle of treatment for simple obesity is weight loss, which is based on dietary restrictions, that is, dietary control and alternative calorie intake. However, the implementation of dietary restrictions lacks a feeling of fullness and satisfaction, and also tends to cause a feeling of hunger, which often causes problems such as a decrease in vitality of life and a stoppage. Conventionally, it has been proposed to provide a material that maintains the feeling of fullness after eating and suppresses the feeling of hunger, but naturally an appropriate amount of energy while obtaining a feeling of fullness and satisfaction without being aware of restrictions at the time of eating. It is considered that the material that can ingest is effective for the practice.

On the other hand, the endosperm of wheat contains about 10 to 15% of protein, and albumin (water-soluble protein), which accounts for about 11% of the protein composition, has mammalian saliva and pancreatic α-amylase inhibitory activity and is postprandial. It has been reported that it has physiological functions such as an action of suppressing an increase in blood glucose and an action of improving insulin resistance (Non-Patent Documents 1 and 2). Among them, the protein 0.26AI that gives a single band at the position of mobility 0.26 by polyacrylamide gel electrophoresis and the protein 0.19AI with a mobility of 0.19 in the same electrophoresis have high α-amylase inhibitory activity. The total content of 0.26AI and 0.19AI is 20% by weight or more and the content of 0.26AI is 20% by weight or more based on the total weight of 0.26AI and 0.19AI. It has been reported that a substance has a high effect on suppressing an increase in blood glucose level and regulating insulin secretion, and can maintain a feeling of fullness after meals to facilitate appetite suppression (Patent Document 1).
However, there are no reports on the effect of the combination of wheat albumin and effervescent ingredients on the amount of food after ingestion.

Japanese Patent No. 3504719

"Pharmacology and Treatment," 2008, Vol. 36, No. 8, p. 761-765 "European Journal of Clinical Nutrition", 2005, Vol. 59, p. 384-392

The present invention relates to providing a pharmaceutical product, a quasi-drug, a food or feed capable of suppressing food intake and suppressing overeating, or a material or preparation which can be blended therein.

The present inventor has conducted intensive research in search of a substance that can naturally ingest an appropriate amount of energy. As a result, a feeling of fullness can be obtained by ingesting a combination of wheat albumin and an effervescent component, and after ingesting that combination, It was found that overeating can be suppressed by suppressing the amount of food intake.

That is, the present invention provides an overeating inhibitor containing (A) wheat albumin, (B) carbonate and (C) organic acid as active ingredients.
The present invention also provides a food for suppressing overeating containing (A) wheat albumin, (B) carbonate and (C) organic acid as active ingredients.
The present invention also provides a method for suppressing overeating, in which foods containing (A) wheat albumin, (B) carbonate and (C) organic acid are ingested.

According to the present invention, eating amount can be suppressed and overeating can be suppressed. If overeating can be suppressed, the energy intake can be optimized, and prevention or improvement of simple obesity due to overeating can be expected.

The graph which shows the result of the VAS evaluation of the feeling of fullness. (A) A graph showing the result of intake. (B) A graph showing the result of calorie intake.

The (A) wheat albumin used in the present invention is a water-soluble protein belonging to the albumin family derived from the endosperm portion of wheat. Wheat albumin has good foaming and foam persistence in the stomach, is easy to obtain a feeling of fullness, and has an excellent effect of suppressing overeating. Therefore, (a) a large amount of wheat albumin having an electrophoresis mobility of 0.19 is used. It is preferable to contain it.
The mobility of electrophoresis here refers to the mobility when a sample is subjected to polyacrylamide gel electrophoresis according to the method of Davis (Annals of the New York Academy of Science, 121, 404-427, 1964). .. In the present specification, wheat albumin having an electrophoresis mobility of 0.19 is also hereinafter referred to as “0.19 wheat albumin”.

The content of (a) 0.19 wheat albumin in (A) wheat albumin is 10 from the viewpoint that foaming and foam persistence in the stomach are good, a feeling of fullness is easily obtained, and an overeating suppressing effect is excellent. It is preferably mass% or more, further 15% by mass or more, further 20% by mass or more, further 25% by mass or more, and from the viewpoint of ease of production, 60% by mass or less, further 40% by mass or less, further 35% by mass or less. Further, it is preferably 31% by mass or less.
Analysis of 0.19 wheat albumin can be performed by HPLC. For example, the method for measuring the content of 0.19 amylase inhibitor described in JP-A-9-172999 can be used.

(A) Wheat albumin can be obtained by extraction from the endosperm portion of wheat. As a method for extracting wheat albumin from wheat, for example, a method for adjusting an amylase inhibitor described in JP-A-9-172999 can be used.
Further, a commercially available product such as wheat albumin NA-1 (Nisshin Pharma Co., Ltd.) may be used.

Examples of the (B) carbonate used in the present invention include sodium carbonate, sodium hydrogencarbonate, potassium carbonate, potassium hydrogencarbonate, calcium carbonate, magnesium carbonate, sodium sesquicarbonate and the like. Of these, sodium carbonate and sodium hydrogen carbonate are preferable, and sodium hydrogen carbonate is even more preferable, from the viewpoint of giving a good flavor.
(B) The carbonate may be used alone or in combination of two or more.
The carbonate analysis can be performed, for example, by the following method.
Take 0.1 to 0.2 g of an analytical sample of carbonate, add 10 mL of water and 2 mL of 50% phosphoric acid, and seal tightly. After sonication for 10 minutes, one hour left headspace gas determine the amount of CO ₂ was subjected to gas chromatography, is calculated from the generated amount of CO _2.
<Gas chromatograph operating conditions>
Model: GC-14B [Shimadzu]
Detector: TCD
Column: Chromosorb 101,80-100 mesh
Glass tube, φ3.2 mm x 2 m
Temperature: Column 50 ° C, inlet and detector 100 ° C
Cell current 75mA
Gas pressure: Helium (carrier gas) 100 kPa
Injection volume: Headspace gas 0.2 mL

As the (C) organic acid used in the present invention, an edible acid can be used. Examples thereof include organic acids such as citric acid, succinic acid, ascorbic acid, acetic acid, gluconic acid, malic acid, tartaric acid, fumaric acid and adipic acid.
Of these, citric acid or malic acid is preferable, and citric acid is more preferable, from the viewpoint of giving a good flavor.
(C) The organic acid may be used alone or in combination of two or more.
The analysis of the organic acid can be performed by, for example, the following method.
Extraction is performed by collecting 1 g of an analysis sample of an organic acid, adding 20 mL of 5% perchloric acid, and shaking for 10 minutes. This is adjusted to 200 mL with water and sonicated for 10 minutes. After filtration, it is subjected to a high performance liquid chromatograph.
<Operating conditions for high performance liquid chromatograph>
Model: LC-20AD [Shimadzu Corporation]
Detector: Ultraviolet-visible absorptiometer SPD-20AV [Shimadzu]
Column temperature: 40 ° C
Mobile phase: 3 mmоl / L perchloric acid reaction solution: 0.2 mmоl / L containing bromothymol blue 15 mmоl / L disodium hydrogen phosphate solution Flow rate: mobile phase 1.0 mL / min, reaction solution 1.4 mL / min
Measurement wavelength: 445 nm

In the present invention, the mass ratio [(A) / (B)] of (A) wheat albumin and (B) carbonate contained in the binge eating inhibitor has good foaming and foam persistence in the stomach. From the viewpoint of easily obtaining a feeling of fullness and having an excellent effect of suppressing overeating, it is preferably 0.3 or more, more preferably 0.5 or more, and preferably 30 or less, more preferably 15 or less, still more preferably 12 or less. , More preferably 8 or less, still more preferably 6 or less.
The mass ratio of (A) wheat albumin to (B) carbonate [(A) / (B)] makes it easier to feel acidity when the value is small, while bitterness and protein due to wheat albumin are large when the value is large. It makes it easier to feel the flavor. Therefore, in consideration of the flavor of the binge eating inhibitor, the mass ratio [(A) / (B)] is preferably 1.5 or more, more preferably 1.6 or more, and further preferably 2.5 or more. It is more preferably 3.0 or more, preferably 8 or less, more preferably 6 or less, still more preferably 5 or less.

In the present invention, the mass ratio [(a) / (B)] of (a) 0.19 wheat albumin and (B) carbonate contained in the binge eating inhibitor is the foaming in the stomach and the persistence of foaming. Is good, it is easy to obtain a feeling of fullness, and it is excellent in the effect of suppressing overeating. Therefore, it is preferably 0.06 or more, more preferably 0.1 or more, further preferably 0.125 or more, and preferably 6 or less. It is more preferably 4.0 or less, still more preferably 3 or less, still more preferably 2.0 or less, still more preferably 1.5 or less.
Further, the mass ratio [(a) / (B)] of (a) 0.19 wheat albumin and (B) carbonate is easy to feel acidity when the value is small, and bitter taste when the value is large. It makes it easier to feel the protein flavor of wheat and albumin. Therefore, in consideration of the flavor of the binge eating inhibitor, the mass ratio [(a) / (B)] is preferably 0.3 or more, more preferably 0.4 or more, and further preferably 0.6 or more. It is more preferably 0.75 or more, preferably 1.8 or less, more preferably 1.5 or less, still more preferably 1.25 or less.

Further, in the present invention, the equivalent ratio of (C) organic acid to (B) carbonate [equivalent of (C) / equivalent of (B)] does not cause the acidity of carbonate-derived harshness or organic acid to stand out. From the viewpoint of improving the balance of flavor, it is preferably 0.3 or more, more preferably 0.7 or more, further preferably 1.0 or more, still more preferably 1.3 or more, and preferably 5 or less. It is more preferably 3.0 or less, still more preferably 2.0 or less, still more preferably 1.6 or less.
The "equivalent ratio" is a value obtained by dividing the equivalent of (C) an organic acid contained in the overeating inhibitor by the equivalent of (B) a carbonate.

The combination of (A) wheat albumin, (B) carbonate and (C) organic acid produces carbon dioxide in the presence of saliva or water in the mouth. In particular, as shown in Examples below, after oral ingestion, it reacts with water in the stomach and foams, and is excellent in foaming and foam persistence in the stomach. Therefore, a feeling of fullness can be obtained by ingesting a combination of (A) wheat albumin, (B) carbonate and (C) organic acid, the amount of food after ingestion can be reduced, and overeating can be suppressed. In addition, by obtaining a feeling of fullness, it is possible to prevent premature eating at the time of subsequent meals and control the amount of food intake. Here, the "feeling of fullness" is a sensation of an individual's internal organs (stomach), and is mainly a sensation caused by the volume and weight of the stomach. This can be judged by a method of comprehensively evaluating the subjective sensation by the visual analog scale (VAS).
That is, the combination of (A) wheat albumin, (B) carbonate and (C) organic acid has an effect of suppressing food intake and suppressing overeating. If eating can be suppressed and overeating can be suppressed, the energy intake can be optimized, and simple obesity due to overeating can be prevented or ameliorated. It also prevents the onset and progression of health disorders such as impaired glucose tolerance, dyslipidemia, hypertension, and hyperuricemia caused by simple obesity, as well as diseases and symptoms such as arteriosclerosis and diabetes. , Can be improved or treated.

Therefore, the combination of (A) wheat albumin, (B) carbonate and (C) organic acid can be a binge eating inhibitor useful for binge eating and binge eating, and for producing the binge eating inhibitor. Can be used for. In addition, the combination of (A) wheat albumin, (B) carbonate and (C) organic acid can be used to suppress the amount of food intake and suppress overeating.
"Use" can be administration or ingestion to a human and may be therapeutic or non-therapeutic use. "Non-therapeutic" is a concept that does not include medical practice, that is, a concept that does not include a method of operating, treating or diagnosing a human, more specifically, a doctor or a person who has been instructed to perform surgery on a human. , A concept that does not include a method of performing treatment or diagnosis.

The overeating inhibitor of the present invention is a drug, quasi-drug, food or feed that exerts an overeating-suppressing effect when ingested or administered to an animal including humans, and the overeating inhibitor is the drug or quasi-drug. It can be a material or formulation used in combination with a product, food or feed.

The foods include foods (foods for specified health use, foods with functional claims) that appeal to suppress overeating and are permitted to label to that effect as necessary. As an example of the display, "You can get a feeling of fullness by taking it before meals. "By taking it before meals, you will feel full and control your weight by keeping the amount of meals appropriate. ] Etc. Foods that have been approved for functional labeling can be distinguished from general foods.

Dosage forms of the above drugs (including quasi-drugs, the same shall apply hereinafter) include, for example, tablets (including chewable tablets, effervescent tablets, etc.), capsules, granules (including effervescent granules, etc.), powders, and troches. , Oral administration with syrup or the like.
Such various dosage forms of the formulations can be prepared of the present invention (A) wheat albumin, (B) carbonate and (C) organic acid, or other pharmaceutically acceptable carriers such as excipients, bonds. Agents, bulking agents, disintegrants, surfactants, lubricants, dispersants, buffers, preservatives, flavoring agents, fragrances, coating agents, carriers, diluents, etc., (A) wheat albumin, (B) It can be prepared by appropriately combining medicinal ingredients other than carbonate and (C) organic acid.
Among them, the preferred dosage form is a solid preparation for oral administration, and tablets are preferable.

The form of the food is preferably solid or semi-solid, and for example, foods and drinks such as jelly, wafers, biscuits, bread, noodles, and sausages, various food compositions such as nutritional foods, and further. Examples thereof include nutritional supplement compositions in the same form as the above-mentioned orally administered preparations (solid preparations such as tablets, capsules and lozenges). Among them, a solid preparation is preferable, and a tablet is more preferable.

Foods of various forms include (A) wheat albumin, (B) carbonates and (C) organic acids, or other food materials, solvents, softeners, oils, emulsifiers, preservatives, acidulants, sweeteners, Prepared by appropriately combining bitterness agents, fragrances, stabilizers, colorants, antioxidants, moisturizers, thickeners, (A) wheat albumin, (B) carbonates, (C) active ingredients other than organic acids, etc. can do.

The form of the feed is preferably pellet, flake or mash, and for example, livestock feed used for cattle, pigs, chickens, sheep, horses, etc., small animal feed used for rabbits, rats, mice, etc. Examples include pet food used for dogs, cats, small birds and the like.

The feed may be (A) wheat albumin, (B) carbonate and (C) organic acids, or other feed materials such as meat, protein, grains, bran, lees, sugars, vegetables, vitamins, minerals. It can be prepared by a conventional method by appropriately combining cereals, gelling agents, mold-retaining agents, pH adjusters, seasonings, preservatives, nutritional supplements and the like.

The content of (A) wheat albumin in the above-mentioned preparation is 5% by mass or more, and further 15% by mass from the viewpoints that foaming and foam persistence in the stomach are good, a feeling of fullness is easily obtained, and an overeating suppressing effect is excellent. % Or more, more preferably 30% by mass or more, further preferably 40% by mass or more, and from the viewpoint of content balance with other active ingredients, 70% by mass or less, further 60% by mass or less, further 46% by mass or less is preferable. ..
The content of (a) 0.19 wheat albumin in the total mass of the preparation is preferably 1% by mass or more, further 3% by mass or more, further 7% by mass or more, further 10% by mass or more, and 20% by mass. Hereinafter, it is preferably 15% by mass or less, and more preferably 12% by mass or less.

The content of (B) carbonate in the total mass of the preparation is 2% by mass or more, preferably 5% by mass or more, more preferably 10% by mass or more, and preferably 40% by mass or less, more preferably 25% by mass. It is mass% or less, more preferably 16 mass% or less.

The content of the organic acid (C) in the total mass of the preparation is 2% by mass or more, preferably 5% by mass or more, more preferably 10% by mass or more, still more preferably 12% by mass or more, and preferably 25% by mass. It is mass% or less, more preferably 20 mass% or less, still more preferably 15 mass% or less.

The dose or intake of the binge eating inhibitor of the present invention may vary depending on the body weight, gender, age, condition or other factors of the subject to be administered or ingested. The dose, route, interval, and amount and interval of ingestion can be appropriately determined by those skilled in the art, but are usually 0 per day for one adult (60 kg), preferably 0 as (A) wheat albumin. It is .25 g or more, and preferably 7.5 g or less.
In addition, usually, (a) 0.19 wheat albumin is preferably 0.06 g or more, and preferably 2 g or less per day for one adult (60 kg).
In the present invention, it is preferable to administer or ingest such an amount once to a plurality of times a day.

The above-mentioned preparation can be administered or ingested according to an arbitrary plan.
The administration or ingestion period is not particularly limited, but it is preferable to administer or ingest repeatedly and continuously, more preferably to administer or ingest continuously for 5 days or more, and to administer or ingest continuously for 15 days or more. More preferred.

The subject to be administered or ingested is not particularly limited as long as it is a human or non-human animal that needs or desires to suppress eating and to suppress overeating, but administration or ingestion by a simple obese person or its reserve army is possible. It is valid.
From the viewpoint of effectively exerting the effect of the binge eating inhibitor of the present invention, it is preferable to administer or ingest it at the time of feeding (feeding) or before feeding (feeding), and from 5 minutes before feeding (feeding). It is more preferable to administer or ingest within 30 minutes and further within 5 minutes before feeding (feeding).

Test Example 1 Foaming Evaluation [Test Product]
Using "wheat albumin NA-1" (manufactured by Nisshin Pharma Co., Ltd., 0.19 wheat albumin content 25% by mass) as wheat albumin (hereinafter the same), the raw material components are mixed according to the composition shown in Table 1. did. Next, tablets (1 g / tablet) were obtained using a single-shot tableting machine (manufactured by RIKEN).

[Evaluation of foaming]
(1) Gastric juice model liquid As the gastric juice model liquid, the first liquid (pH 1.2) (manufactured by Kanto Chemical Co., Inc.) of the disintegration test based on the 16th edition revised Japanese Pharmacopoeia was used.
(2) Measurement of measured amount (mL) For the measured amount (mL) of foam, put 1 g of a sample in a 50 mL graduated cylinder, add 2 mL of the above gastric juice model solution, set 0 minutes immediately after the addition, and set the upper part of the foam 10 minutes later. I read the scale of.
Table 1 shows the measured amount (mL) of each.

As is clear from Table 1, the combination of wheat albumin, carbonate and organic acid has a high measured amount (mL) after 10 minutes, foams well in the stomach, and the generated foam is excellent in sustainability. It was confirmed that.

Test Example 2 Flavor Evaluation [Test Product]
The same tablets (1 g / tablet) as in Test Example 1 were used.

[Evaluation of acidity]
Sensory evaluation was performed by three specialized panels. The evaluation was carried out according to the criteria shown below regarding the strength of the sourness felt when the sample was eaten, and the score was determined by consultation. The results are shown in Table 2.
(Strength of acidity)
5: Very weak acidity 4: Weak acidity 3: Slightly strong acidity 2: Strong acidity 1: Very strong acidity

[Evaluation of bitterness]
The intensity of bitterness felt when the sample was eaten was sensory evaluated according to the criteria shown below, and the score was determined through discussions with a specialized panel in the same way as the evaluation of acidity. The results are shown in Table 3.
(Strength of bitterness)
5: Very weak bitterness 4: Weak bitterness 3: Slightly strong bitterness 2: Strong bitterness 1: Very strong bitterness

As is clear from Tables 2 and 3, the tablets of Examples 1 to 7 and 9, especially Examples 3, 4 and 9, had a good flavor.

Test Example 3 Evaluation of satiety [test product]
In the same manner as above, tablets (1 g / tablet) having the compositions shown in Table 4 were prepared.

[Examination outline]
(1) Subjects and methods A test was conducted using a crossover design on 27 healthy men and women. There were four types of test products: wheat albumin effervescent tablets, effervescent tablets, wheat albumin tablets, and placebo tablets, and the subjects evaluated all the test products. The test product was evaluated before lunch.
Have the subject take one tablet of the test product, and based on the time of ingestion of the test product (0 minutes), 1 minute before (-1 minute) of ingestion, 1 minute, 3 minutes, 5 minutes, 7 minutes after ingestion, After 10 minutes, the feeling of fullness was evaluated by a visual analog scale (VAS). Specifically, the left end 0 mm of the 100 mm straight line is expressed as "I am not full at all" (numerical value 0), and the right end 100 mm is expressed as "I am fuller than this" (numerical value 100). Marking was performed on a straight line of 100 mm based on the expressions shown on the left and right ends.

(2) Results Wheat albumin effervescent tablets, effervescent tablets, wheat albumin tablets, and placebo tablets were ingested on different days, and 27 subjects who completed the test were included in the final analysis. The value 1 minute before ingestion (-1 minute) was corrected to 0 as the initial value.
The values (VAS values) of the 27 final analysis subjects up to 1 minute, 3 minutes, 5 minutes, 7 minutes, and 10 minutes later were the same as the values 1 minute before (-1 minute) ingestion in each group. The difference (Δ value) was calculated. The group comparison was performed by Wilcoxon signed rank sum test. The results are shown in FIG.

As is clear from FIG. 1, in the wheat albumin foaming group, a statistically significant increase in satiety was observed as compared with the placebo group and the placebo group (★★ 0.05 ＞ ★＞ 0.1: with the placebo group. Comparison, ** 0.05 >> 0.1: Comparison with wheat albumin group, 〇> 0.05: Comparison with foaming group).

Test Example 4 Effect on food intake [Test product]
Wheat albumin effervescent tablets and wheat albumin tablets (1 g / tablet) shown in Table 4 were used.

[Test meal]
Test food Meal test C (manufactured by Saraya Co., Ltd.) was used as the test food. This is a load diet that can be used to evaluate glucose metabolism, lipid metabolism, and insulin secretory capacity. As for barley tea, 3 bottles of "Rokujo barley tea" (manufactured by Asahi Soft Drinks Co., Ltd., 100 mL) were used and were taken freely.

[Examination outline]
(1) Subjects and methods A crossover design test was conducted on 17 healthy men and women. There were two types of test products, wheat albumin effervescent tablets and wheat albumin tablets, and the subjects evaluated all the test products. The test product was evaluated before lunch.
Have the subject take one tablet of the test product, start taking the test meal 5 minutes after ingestion based on the time of taking the test product (0 minutes), and take the test meal when a comfortable feeling of fullness is felt. Was terminated.
After the intake was completed, the intake amount and calorie intake of the test meal were measured.

(2) Results All the subjects were selected as the final analysis subjects, and the intake and calorie intake of each group are shown in Fig. 2. Numerical values were shown as mean ± standard error, and comparison between groups was performed by significant difference test by paired t-test.
As is clear from FIG. 2, it was confirmed that the wheat albumin foaming group suppressed the intake amount and the calorie intake as compared with the wheat albumin group, and as a result, it was useful for suppressing overeating.

Claims (12)

An overeating inhibitor containing (A) wheat albumin, (B) carbonate and (C) organic acid as active ingredients. The overeating inhibitor according to claim 1, wherein (A) wheat albumin contains (a) 0.19 wheat albumin in an amount of 10 to 60% by mass. The overeating inhibitor according to claim 1 or 2, wherein the mass ratio [(A) / (B)] of (A) wheat albumin to (B) carbonate is 0.3 to 30. (A) The overeating inhibitor according to any one of claims 1 to 3, wherein the mass ratio [(a) / (B)] of 0.19 wheat albumin to (B) carbonate is 0.06 to 6. .. The overeating inhibitor according to any one of claims 1 to 4, wherein the equivalent ratio of (C) organic acid to (B) carbonate [equivalent of (C) / equivalent of (B)] is 0.3 to 5. .. The overeating inhibitor according to any one of claims 1 to 5, wherein the dosage form is an oral solid preparation. A food for suppressing overeating containing (A) wheat albumin, (B) carbonate and (C) organic acid as active ingredients. The food for suppressing overeating according to claim 7, wherein (A) wheat albumin contains (a) 0.19 wheat albumin in an amount of 10 to 60% by mass. The food for suppressing overeating according to claim 7 or 8, wherein the mass ratio [(A) / (B)] of (A) wheat albumin and (B) carbonate is 0.3 to 30. (A) 0.19 For suppressing overeating according to any one of claims 7 to 9, wherein the mass ratio [(a) / (B)] of wheat albumin to (B) carbonate is 0.06 to 6. Food. The overeating inhibitor according to any one of claims 7 to 10, wherein the equivalent ratio of (C) organic acid to (B) carbonate [equivalent of (C) / equivalent of (B)] is 0.3 to 5. Food. The food for suppressing overeating according to any one of claims 7 to 11 , wherein the dosage form is an oral solid preparation.

Images